Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $420 (market cap $2.01T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 226.4× Kymera Therapeutics Inc. Common Stock's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.94% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Taiwan Semiconductor Mfg. Co. Ltd. for 111 Days on average.
| KYMR | TSM | |
|---|---|---|
Market Cap | $8.88B | $2.01T |
Volume | 1,028,790 | 14,977,146 |
Sector | Health | Technology |
52-Week High | $127.31 | $485.80 |
52-Week Low | $55.80 | $275.06 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $8.27B | $1.93T |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TSMC (TSM) trades at $445.12, up 0.17% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue and net income have shown robust growth, with 2025 revenue at $3.81T and net income at $1.70T. Analyst sentiment is overwhelmingly positive, with a consensus price target of $578.43, representing significant upside. Recent news highlights TSMC's pivotal role in AI chip manufacturing and upcoming dividend payments.
The outlook for TSM is favorable, driven by strong earnings momentum, high profitability margins, and its dominant position in semiconductor manufacturing. Key opportunities include continued AI-driven demand and technological leadership. Risks involve geopolitical tensions, competitive pressures, and market volatility. The stock presents a compelling long-term investment case supported by analyst optimism and solid financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
